Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection

References

• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–1315. doi: 10.1016/S0140-6736(84)91816-6
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of campylobacter pylori. Lancet. 1988;2(8626–8627):1437–1442. doi: 10.1016/S0140-6736(88)90929-4
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19. doi: 10.1038/s41572-023-00431-8
   PubMed Web of Science ®Google Scholar
• Wang SW, Yu FJ, Kuo FC, et al. Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts. Therap Adv Gastroenterol. 2023;16:17562848231170941. doi: 10.1177/17562848231170941
   Web of Science ®Google Scholar
• Sachs G, Wen Y, Scott DR. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2009;11(6):455–461. doi: 10.1007/s11894-009-0070-y
   PubMedGoogle Scholar
• Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338–349. doi: 10.1038/s41571-023-00747-0
   PubMed Web of Science ®Google Scholar
• Reyes VE. Helicobacter pylori and its role in gastric cancer. Microorganisms. 2023;11(5):1312. doi: 10.3390/microorganisms11051312
   PubMed Web of Science ®Google Scholar
• Xiong M, Yu C, Ren B, et al. Global knowledge mapping and emerging trends in Helicobacter pylori-related precancerous lesions of gastric cancer research: a bibliometric analysis from 2013 to 2023. Medicine (Baltimore). 2023;102(48):e36445. doi: 10.1097/MD.0000000000036445
   PubMed Web of Science ®Google Scholar
• Lim MCC, Jantaree P, Naumann M. The conundrum of Helicobacter pylori-associated apoptosis in gastric cancer. Trends Cancer. 2023;9(8):679–690. doi: 10.1016/j.trecan.2023.04.012
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Bashir AHH, Aljarbou AN, et al. The possible role of Helicobacter pylori in gastric cancer and its management. Front Oncol. 2019 Feb 22;9:75. doi: 10.3389/fonc.2019.00075
   PubMed Web of Science ®Google Scholar
• Bulajic M, Panic N, Löhr JM. Helicobacter pylori and pancreatic diseases. World J Gastrointest Pathophysiol. 2014;5(4):380–383. doi: 10.4291/wjgp.v5.i4.380
   PubMedGoogle Scholar
• Aramouni K, Assaf RK, Azar M, et al. Infection with Helicobacter pylori may predispose to atherosclerosis: role of inflammation and thickening of intima-media of carotid arteries. Front Pharmacol. 2023;14:1285754. doi: 10.3389/fphar.2023.1285754
   PubMed Web of Science ®Google Scholar
• Chen X, Peng R, Peng D, et al. An update: is there a relationship between H. pylori infection and nonalcoholic fatty liver disease? why is this subject of interest? Front Cell Infect Microbiol. 2023;13:1282956. doi: 10.3389/fcimb.2023.1282956
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu Y, Wu L, et al. Causal effect of gut microbiota on gastroduodenal ulcer: a two-sample Mendelian randomization study. Front Cell Infect Microbiol. 2023;13:1322537. doi: 10.3389/fcimb.2023.1322537
   PubMed Web of Science ®Google Scholar
• Thorell K, Muñoz-Ramírez ZY, Wang D, et al. The Helicobacter pylori genome project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes. Nat Commun. 2023;14(1):8184. doi: 10.1038/s41467-023-43562-y
   PubMed Web of Science ®Google Scholar
• Morishita S, Nishimori I, Minakuchi T, et al. Cloning, polymorphism, and inhibition of beta-carbonic anhydrase of Helicobacter pylori. J Gastroenterol. 2008;43(11):849–857. doi: 10.1007/s00535-008-2240-3
   PubMed Web of Science ®Google Scholar
• Abbondio M, Tanca A, De Diego L, et al. Metaproteomic assessment of gut microbial and host functional perturbations in Helicobacter pylori-infected patients subjected to an antimicrobial protocol. Gut Microbes. 2023;15(2):2291170. doi: 10.1080/19490976.2023.2291170
   PubMed Web of Science ®Google Scholar
• Buzás GM, Birinyi P. Newer, older, and alternative agents for the eradication of Helicobacter pylori infection: a narrative review. Antibiotics. 2023;12(6):946. doi: 10.3390/antibiotics12060946
   Google Scholar
• Borao Laguna C, Lanas A. Advances in the pharmacotherapeutic management of refractory peptic ulcers. Expert Opin Pharmacother. 2023;24(7):825–833. doi: 10.1080/14656566.2023.2199922
   PubMed Web of Science ®Google Scholar
• Ho JJC, Argueta EA, Moss SF. Helicobacter pylori treatment regimens: a US perspective. Gastroenterol Hepatol (NY). 2022;18(6):313–319.
   PubMedGoogle Scholar
• Shrestha AB, Pokharel P, Sapkota UH, et al. Drug resistance patterns of commonly used antibiotics for the treatment of Helicobacter pylori infection among south Asian countries: a systematic review and meta-analysis. Trop Med Infect Dis. 2023;8(3):172. doi: 10.3390/tropicalmed8030172
   PubMedGoogle Scholar
• de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: a systematic review. World J Gastroenterol. 2023;29(2):390–409. doi: 10.3748/wjg.v29.i2.390
   PubMed Web of Science ®Google Scholar
• Rokkas T, Ekmektzoglou K. Advances in the pharmacological and regulatory management of multidrug resistant Helicobacter pylori. Expert Rev Clin Pharmacol. 2023;16(12):1229–1237. doi: 10.1080/17512433.2023.2282061
   PubMedGoogle Scholar
• Hong TC, El-Omar EM, Kuo YT, et al. Asian pacific alliance on Helicobacter and microbiota. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(1):56–67. doi: 10.1016/S2468-1253(23)00281-9
   PubMed Web of Science ®Google Scholar
• Wei W, Wang Z, Li C, et al. Antibiotic resistance of Helicobacter pylori in Nanjing, China: a cross-section study from 2018 to 2023. Front Cell Infect Microbiol. 2023;13:1294379. doi: 10.3389/fcimb.2023.1294379
   PubMed Web of Science ®Google Scholar
• Srisuphanunt M, Wilairatana P, Kooltheat N, et al. Molecular mechanisms of antibiotic resistance and novel treatment strategies for Helicobacter pylori infections. Trop Med Infect Dis. 2023;8(3):163. doi: 10.3390/tropicalmed8030163
   PubMedGoogle Scholar
• Vita NA, Anderson SM, LaFleur MD, et al. Targeting Helicobacter pylori for antibacterial drug discovery with novel therapeutics. Cur Opin Microbio. 2022;70:102203. doi: 10.1016/j.mib.2022.102203
   PubMed Web of Science ®Google Scholar
• Plotniece A, Sobolev A, Supuran CT, et al. Selected strategies to fight pathogenic bacteria. J Enzyme Inhibit Med Chem. 2023;38(1):2155816. doi: 10.1080/14756366.2022.2155816
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Coombs N, Patel L, et al. Identification of Antimotilins, novel inhibitors of Helicobacter pylori flagellar motility that inhibit stomach colonization in a mouse Model. MBio. 2022;13(2):e0375521. doi: 10.1128/mbio.03755-21
   PubMed Web of Science ®Google Scholar
• Buzás GM, Supuran CT. The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Puşcaş (1932-2015). J Enzyme Inhib Med Chem. 2016;31(4):527–533. doi: 10.3109/14756366.2015.1051042
   PubMed Web of Science ®Google Scholar
• Chirica LC, Elleby B, Lindskog S. Cloning, expression and some properties of alpha-carbonic anhydrase from Helicobacter pylori. Biochim Biophys Acta. 2001;1544(1–2):55–63. doi: 10.1016/S0167-4838(00)00204-1
   PubMedGoogle Scholar
• Chirica LC, Petersson C, Hurtig M, et al. Expression and localization of alpha- and beta-carbonic anhydrase in Helicobacter pylori. Biochim Biophys Acta. 2002;1601(2):192–199. doi: 10.1016/S1570-9639(02)00467-3
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181. doi: 10.1038/nrd2467
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase versatility: from pH regulation to CO2 sensing and metabolism. Front Mol Biosci. 2023 Nov 10;10:1326633. doi: 10.3389/fmolb.2023.1326633
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8(2):25. doi: 10.3390/metabo8020025
   PubMed Web of Science ®Google Scholar
• Marcus EA, Moshfegh AP, Sachs G, et al. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187(2):729–738. doi: 10.1128/JB.187.2.729-738.2005
   PubMed Web of Science ®Google Scholar
• Scott DR, Marcus EA, Wen Y, et al. Cytoplasmic histidine kinase (HP0244)-regulated assembly of urease with UreI, a channel for urea and its metabolites, CO2, NH3, and NH4(+), is necessary for acid survival of Helicobacter pylori. J Bacteriol. 2010;192(1):94–103. doi: 10.1128/JB.00848-09
   PubMed Web of Science ®Google Scholar
• Wen Y, Feng J, Scott DR, et al. The HP0165-HP0166 two-component system (ArsRS) regulates acid-induced expression of HP1186 alpha-carbonic anhydrase in Helicobacter pylori by activating the pH-dependent promoter. J Bacteriol. 2007;189(6):2426–2434. doi: 10.1128/JB.01492-06
   PubMed Web of Science ®Google Scholar
• Wen Y, Feng J, Scott DR, et al. Involvement of the HP0165-HP0166 two-component system in expression of some acidic-pH-upregulated genes of Helicobacter pylori. J Bacteriol. 2006;188(5):1750–1761. doi: 10.1128/JB.188.5.1750-1761.2006
   PubMed Web of Science ®Google Scholar
• Sachs G, Weeks DL, Wen Y, et al. Acid acclimation by Helicobacter pylori. Physiology. 2005 Dec;20(6):429–438. doi: 10.1152/physiol.00032.2005
   PubMedGoogle Scholar
• Bury-Moné S, Mendz GL, Ball GE, et al. Roles of alpha and beta carbonic anhydrases of Helicobacter pylori in the urease-dependent response to acidity and in colonization of the murine gastric mucosa. Infect Immun. 2008;76(2):497–509. doi: 10.1128/IAI.00993-07
   PubMed Web of Science ®Google Scholar
• Supuran CT. An overview of novel antimicrobial carbonic anhydrase inhibitors. Expert Opin Ther Targets. 2023;27(10):897–910. doi: 10.1080/14728222.2023.2263914
   PubMed Web of Science ®Google Scholar
• Flaherty DP, Seleem MN, Supuran CT. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem. 2021 Oct;13(19):1619–1622. doi: 10.4155/fmc-2021-0207
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat. 2020;30(12):963–982. doi: 10.1080/13543776.2020.1811853
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT, Capasso C. An overview on the recently discovered iota-carbonic anhydrases. J Enzyme Inhib Med Chem. 2021;36(1):1988–1995. doi: 10.1080/14756366.2021.1972995
   PubMed Web of Science ®Google Scholar
• Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond). 2021;135(10):1233–1249. doi: 10.1042/CS20210040
   PubMed Web of Science ®Google Scholar
• Fantacuzzi M, D’Agostino I, Carradori S, et al. Benzenesulfonamide derivatives as Vibrio cholerae carbonic anhydrases inhibitors: a computational-aided insight in the structural rigidity-activity relationships. J Enzyme Inhib Med Chem. 2023;38(1):2201402. doi: 10.1080/14756366.2023.2201402
   PubMed Web of Science ®Google Scholar
• An W, Holly KJ, Nocentini A, et al. Structure-activity relationship studies for inhibitors for vancomycin-resistant enterococcus and human carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):1838–1844. doi: 10.1080/14756366.2022.2092729
   PubMed Web of Science ®Google Scholar
• Abutaleb NS, Elhassanny AEM, Nocentini A, et al. Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2022;37(1):51–61. doi: 10.1080/14756366.2021.1991336
   PubMed Web of Science ®Google Scholar
• Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021;7(7):1969–1984. doi: 10.1021/acsinfecdis.1c00055
   PubMed Web of Science ®Google Scholar
• Abutaleb NS, Elhassanny AEM, Seleem MN. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microb Pathog. 2022;164:105454. doi: 10.1016/j.micpath.2022.105454
   PubMed Web of Science ®Google Scholar
• Kaur J, Cao X, Abutaleb NS, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem. 2020;63(17):9540–9562. doi: 10.1021/acs.jmedchem.0c00734
   PubMed Web of Science ®Google Scholar
• Chilambi GS, Wang YH, Wallace NR, et al. Carbonic anhydrase inhibition as a target for antibiotic synergy in enterococci. Microbiol Spectr. 2023;11(4):e0396322. doi: 10.1128/spectrum.03963-22
   PubMed Web of Science ®Google Scholar
• Abutaleb NS, Shrinidhi A, Bandara AB, et al. Evaluation of 1,3,4-thiadiazole carbonic anhydrase inhibitors for gut decolonization of vancomycin-resistant enterococci. ACS Med Chem Lett. 2023;14(4):487–492. doi: 10.1021/acsmedchemlett.3c00032
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580. doi: 10.1080/14756366.2021.1882453
   PubMed Web of Science ®Google Scholar
• Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: carbonic anhydrase, its inhibition and activation. Bioorg Med Chem Lett. 2023;93:129411. doi: 10.1016/j.bmcl.2023.129411
   PubMed Web of Science ®Google Scholar
• Giovannuzzi S, Hewitt CS, Nocentini A, et al. Inhibition studies of bacterial α-carbonic anhydrases with phenols. J Enzyme Inhib Med Chem. 2022;37(1):666–671. doi: 10.1080/14756366.2022.2038592
   PubMed Web of Science ®Google Scholar
• Nocentini A, Osman SM, Del Prete S, et al. Extending the γ-class carbonic anhydrases inhibition profiles with phenolic compounds. Bioorganic Chem. 2019;93:103336. doi: 10.1016/j.bioorg.2019.103336
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors from Marine natural products. Mar Drugs. 2022;20(11):721. doi: 10.3390/md20110721
   PubMed Web of Science ®Google Scholar
• Cau Y, Mori M, Supuran CT, et al. Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations. Org Biomol Chem. 2016;14(35):8322–8330. doi: 10.1039/C6OB01477A
   PubMed Web of Science ®Google Scholar
• Giovannuzzi S, Abutaleb NS, Hewitt CS, et al. Dithiocarbamates effectively inhibit the α-carbonic anhydrase from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem. 2022;37(1):1–8. doi: 10.1080/14756366.2021.1988945
   PubMed Web of Science ®Google Scholar
• Aspatwar A, Hammarén M, Koskinen S, et al. β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem. 2017;32(1):832–840. doi: 10.1080/14756366.2017.1332056
   PubMed Web of Science ®Google Scholar
• Giovannuzzi S, Marapaka AK, Abutaleb NS, et al. Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamates. J Enzyme Inhib Med Chem. 2023;38(1):2284119. doi: 10.1080/14756366.2023.2284119
   PubMedGoogle Scholar
• Giovannuzzi S, Hewitt CS, Nocentini A, et al. Coumarins effectively inhibit bacterial α-carbonic anhydrases. J Enzyme Inhib Med Chem. 2022;37(1):333–338. doi: 10.1080/14756366.2021.2012174
   PubMed Web of Science ®Google Scholar
• Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhib Med Chem. 2020;35(1):1462–1470. doi: 10.1080/14756366.2020.1788009
   PubMed Web of Science ®Google Scholar
• Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann NY Acad Sci. 1984;429(1):587–591. doi: 10.1111/j.1749-6632.1984.tb12392.x
   PubMedGoogle Scholar
• Puscas I, Buzás G. Treatment of duodenal ulcers with ethoxzolamide, an inhibitor of gastric mucosa carbonic anhydrase. Int J Clin Pharmacol Ther Toxicol. 1986;24(2):97–99.
   PubMedGoogle Scholar
• Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem. 2006;49(6):2117–2126. doi: 10.1021/jm0512600
   PubMed Web of Science ®Google Scholar
• Nishimori I, Vullo D, Minakuchi T, et al. Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori. Bioorg Med Chem Lett. 2006;16(8):2182–2188. doi: 10.1016/j.bmcl.2006.01.044
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett. 2007;17(13):3585–3594. doi: 10.1016/j.bmcl.2007.04.063
   PubMed Web of Science ®Google Scholar
• Nishimori I, Onishi S, Takeuchi H, et al. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des. 2008;14(7):622–630. doi: 10.2174/138161208783877875
   PubMed Web of Science ®Google Scholar
• Modak JK, Liu YC, Machuca MA, et al. Structural basis for the inhibition of Helicobacter pylori α-carbonic anhydrase by sulfonamides. PLoS One. 2015;10(5):e0127149. doi: 10.1371/journal.pone.0127149
   PubMed Web of Science ®Google Scholar
• Modak JK, Liu YC, Supuran CT, et al. Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem. 2016;59(24):11098–11109. doi: 10.1021/acs.jmedchem.6b01333
   PubMed Web of Science ®Google Scholar
• Compostella ME, Berto P, Vallese F, et al. Structure of α-carbonic anhydrase from the human pathogen Helicobacter pylori. Acta Crystallogr F Struct Biol Commun. 2015;71(Pt 8):1005–1011. doi: 10.1107/S2053230X15010407
   PubMedGoogle Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112(8):4421–4468. doi: 10.1021/cr200176r
   PubMed Web of Science ®Google Scholar
• Modak JK, Tikhomirova A, Gorrell RJ, et al. Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem. 2019;34(1):1660–1667. doi: 10.1080/14756366.2019.1663416
   PubMed Web of Science ®Google Scholar
• Rahman MM, Tikhomirova A, Modak JK, et al. Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathog. 2020;12(1):20. doi: 10.1186/s13099-020-00358-5
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31(3):345–360. doi: 10.3109/14756366.2015.1122001
   PubMed Web of Science ®Google Scholar
• Campestre C, De Luca V, Carradori S, et al. Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol. 2021;12:629163. doi: 10.3389/fmicb.2021.629163
   PubMed Web of Science ®Google Scholar
• Grande R, Carradori S, Puca V, et al. Selective inhibition of Helicobacter pylori carbonic anhydrases by Carvacrol and thymol could impair biofilm production and the release of outer membrane vesicles. Int J Mol Sci. 2021;22(21):11583. doi: 10.3390/ijms222111583
   PubMed Web of Science ®Google Scholar
• Puca V, Turacchio G, Marinacci B, et al. Antimicrobial and antibiofilm activities of carvacrol, amoxicillin and salicylhydroxamic acid alone and in combination vs. Helicobacter pylori: towards a new multi-targeted therapy. Int J Mol Sci. 2023;24(5):4455. doi: 10.3390/ijms24054455
   PubMed Web of Science ®Google Scholar
• Ronci M, Del Prete S, Puca V, et al. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori. J Enzyme Inhib Med Chem. 2019;34(1):189–195. doi: 10.1080/14756366.2018.1539716
   PubMed Web of Science ®Google Scholar
• Maresca A, Vullo D, Scozzafava A, et al. Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions. J Enzyme Inhib Med Chem. 2013;28(2):388–391. doi: 10.3109/14756366.2011.649268
   PubMed Web of Science ®Google Scholar
• Angeli A, Ferraroni M, Supuran CT. Famotidine, an antiulcer agent, strongly inhibits Helicobacter pylori and human carbonic anhydrases. ACS Med Chem Lett. 2018;9(10):1035–1038. doi: 10.1021/acsmedchemlett.8b00334
   PubMed Web of Science ®Google Scholar
• Angeli A, Pinteala M, Maier SS, et al. Inhibition of bacterial α-, β- and γ-class carbonic anhydrases with selenazoles incorporating benzenesulfonamide moieties. J Enzyme Inhib Med Chem. 2019;34(1):244–249. doi: 10.1080/14756366.2018.1547287
   PubMed Web of Science ®Google Scholar
• Benito G, D’Agostino I, Carradori S, et al. Erlotinib-containing benzenesulfonamides as anti-Helicobacter pylori agents through carbonic anhydrase inhibition. Future Med Chem. 2023;15(20):1865–1883. doi: 10.4155/fmc-2023-0208
   PubMedGoogle Scholar
• Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct–an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett. 2010;20(2):474–478. doi: 10.1016/j.bmcl.2009.11.124
   PubMed Web of Science ®Google Scholar
• Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate. Bioorg Med Chem Lett. 2010;20(5):1548–1550. doi: 10.1016/j.bmcl.2010.01.081
   PubMed Web of Science ®Google Scholar
• Campoli-Richards DM, Clissold SP. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986;32(3):197–221. doi: 10.2165/00003495-198632030-00001
   PubMed Web of Science ®Google Scholar
• Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther. 1996;18(1):36–54. doi: 10.1016/S0149-2918(96)80177-9
   PubMed Web of Science ®Google Scholar
• Kim J, Kim N, Park JH, et al. The effect of Helicobacter pylori on epidermal growth factor receptor-induced signal transduction and the preventive effect of celecoxib in gastric cancer cells. Gut Liver. 2013;7(5):552–559. doi: 10.5009/gnl.2013.7.5.552
   PubMed Web of Science ®Google Scholar
• Chichirau BE, Diechler S, Posselt G, et al. Tyrosine kinases in Helicobacter pylori infections and gastric cancer. Toxins (Basel). 2019;11(10):591. doi: 10.3390/toxins11100591
   PubMed Web of Science ®Google Scholar
• Piperdi B, Perez-Soler R. Role of Erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs. 2012;72(1):11–19. doi: 10.2165/1163018-S0-000000000-00000
   PubMedGoogle Scholar
• Starling N, Neoptolemos J, Cunningham D. Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag. 2006;2(4):435. doi: 10.2147/tcrm.2006.2.4.435
   PubMedGoogle Scholar
• Angeli A, Supuran CT. Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications. J Enzyme Inhib Med Chem. 2023;38(1):2166503. doi: 10.1080/14756366.2023.2166503
   PubMed Web of Science ®Google Scholar